Active Mouse Urokinase, HMW

$285$515

Clear
SKU: MUPA Categories: ,

Product Description

Active Mouse Urokinase, HMW

Active two-chain HMW mouse urokinase, recombinantly produced in insect cells.

Gene ID: 18792

Swiss-Prot/UniProt ID: P06869

View sample datasheet

View sample certificate of analysis

View material safety data sheet

Ask a question about this product

Additional Information

Purity

Source

Molecular Weight

Extinction Coefficient

Species

Storage

Shipping Conditions

Expiration

Form

Buffer

Sample Size

Sample Concentration

Sample Volume

Gene Name

Gene ID

UniProt ID

1. Merchan JR, Tang J, Hu G et-al. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J. Natl. Cancer Inst. 2006;98 (11): 756-64. doi:10.1093/jnci/djj208Pubmed citation

2. Suelves M, Vidal B, Serrano AL et-al. uPA deficiency exacerbates muscular dystrophy in MDX mice. J. Cell Biol. 2007;178 (6): 1039-51. doi:10.1083/jcb.200705127Free text at pubmedPubmed citation

3. Bryer SC, Fantuzzi G, Van rooijen N et-al. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J. Immunol. 2008;180 (2): 1179-88. J. Immunol. (link)Pubmed citation

4. Ilkovitch D, Handel-fernandez ME, Herbert LM et-al. Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells. Cancer Res. 2008;68 (7): 2427-35. doi:10.1158/0008-5472.CAN-07-5651Pubmed citation

5. Van den broeck T, Stevenaert F, Taveirne S et-al. Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator. Blood. 2008;112 (13): 5046-51. doi:10.1182/blood-2008-06-164350Pubmed citation

6. Jo M, Takimoto S, Montel V et-al. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am. J. Pathol. 2009;175 (1): 190-200. doi:10.2353/ajpath.2009.081053Free text at pubmedPubmed citation

8. Sisson TH, Nguyen MH, Yu B et-al. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration. Blood. 2009;114 (24): 5052-61. doi:10.1182/blood-2008-12-196212Free text at pubmedPubmed citation

9. Botkjaer KA, Deryugina EI, Dupont DM et-al. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. Mol. Cancer Res. 2012;10 (12): 1532-43. doi:10.1158/1541-7786.MCR-12-0349Free text at pubmedPubmed citation

10. Ilkovitch D, Carrio R, Lopez DM. uPA and uPA-receptor are involved in cancer-associated myeloid-derived suppressor cell accumulation. Anticancer Res. 2012;32 (10): 4263-70. Anticancer Res. (link)Pubmed citation

11. Sanderson-smith ML, Zhang Y, Ly D et-al. A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. PLoS Pathog. 2013;9 (7): e1003469. doi:10.1371/journal.ppat.1003469Free text at pubmedPubmed citation

12. Wu F, Catano M, Echeverry R, et al. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke. J Neurosci. 2014;34(43):14219-32. Link to article

13. Endo-munoz L, Cai N, Cumming A, et al. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis. PLoS ONE. 2015;10(8):e0133592. Link to article.

14. Cooper JM, Rastogi A, Krizo JA, Mintz EM, Prosser RA. Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice. Eur J Neurosci. 2016; Link to article

15. Dupont DM, Madsen JB, Hartmann RK, et al. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. RNA. 2010;16(12):2360-9. Link to article

16. Magnussen SN, Hadler-olsen E, Costea DE, et al. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion. BMC Cancer. 2017;17(1):350. Link to article